ProCE Banner Activity

Understanding HER2-Low Breast Cancer: Current Challenges and Emerging Opportunities for Treatment

Clinical Thought
What I want my colleagues to know about distinguishing patients with HER2-low breast cancer and emerging data on potential treatment options.

Released: March 24, 2022

Expiration: March 23, 2023

Share

Faculty

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Q Synthesis LLC

ProCE Banner

Faculty Disclosure

Primary Author

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Pieris, PUMA, Radius, Sanofi, Seattle Genetics/Seagen, and Zymeworks.